Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OABI
stocks logo

OABI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.00M
-16.67%
-0.087
-27.08%
5.88M
+41.6%
-0.110
-35.29%
5.67M
+45.4%
-0.115
-23.33%
Estimates Revision
The market is revising Downward the revenue expectations for OmniAb, Inc. (OABI) for FY2025, with the revenue forecasts being adjusted by -11.11% over the past three months. During the same period, the stock price has changed by 15.20%.
Revenue Estimates for FY2025
Revise Downward
down Image
-11.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.84%
In Past 3 Month
Stock Price
Go Up
up Image
+15.20%
In Past 3 Month
Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.970
sliders
Low
3.00
Averages
6.00
High
11.00
Current: 1.970
sliders
Low
3.00
Averages
6.00
High
11.00
Craig-Hallum
Buy
downgrade
$10 -> $7
2025-11-05
Reason
Craig-Hallum
Price Target
$10 -> $7
2025-11-05
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.
RBC Capital
Conor McNamara
Buy
Maintains
$7 → $4
2025-03-27
Reason
RBC Capital
Conor McNamara
Price Target
$7 → $4
2025-03-27
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on OmniAb to $4 from $7 and keeps an Outperform rating on the shares. The company provided lower than expected FY25 revenue guidance, though the outlook is prudent and de-risks lumpy contributions due to its partner's program progression, the analyst tells investors in a research note. RBC adds that its takeaways from OmniAb Q4 include continued program growth with healthy end markets and its view that FY25 revenue guide is achievable with lower cash spend.
Benchmark
Robert Wasserman
Strong Buy
Maintains
$8 → $6
2025-03-20
Reason
Benchmark
Robert Wasserman
Price Target
$8 → $6
2025-03-20
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$11
2025-03-19
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$11
2025-03-19
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for OmniAb Inc (OABI.O) is -4.61, compared to its 5-year average forward P/E of -7.80. For a more detailed relative valuation and DCF analysis to assess OmniAb Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.80
Current PE
-4.61
Overvalued PE
-4.51
Undervalued PE
-11.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-5.77
Undervalued EV/EBITDA
-11.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.29
Current PS
0.00
Overvalued PS
16.41
Undervalued PS
8.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OABI News & Events

Events Timeline

(ET)
2025-11-17
17:26:08
OmniAb Enters Partnership for Antibody Discovery with Newly Incubated Firm
select
2025-11-04 (ET)
2025-11-04
16:19:13
OmniAb projects FY25 revenue between $18M and $22M, with consensus at $21.7M.
select
2025-11-04
16:18:40
OmniAb Announces Q3 Earnings Per Share of 14 Cents, Matching Expectations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-18Newsfilter
OmniAb Signs Technology License and Services Agreement for Antibody Discovery with New Incubated Firm from ArrowMark Partners and Viking Global Investors

  • Agreement Overview: OmniAb, Inc. has signed a license and services agreement with ArrowMark Partners for antibody discovery programs through its OmniAb-derived technology, which includes revenue, equity, and royalties for services provided.

  • Strategic Partnership: The collaboration with ArrowMark and Viking Global Investors aims to leverage OmniAb's innovative transgenic chicken-based technologies to identify next-generation drug targets and enhance value creation in biotech investments.

  • OmniAb's Technology: OmniAb specializes in advanced discovery research technology that enables the rapid identification of optimal antibodies for therapeutic development, utilizing a diverse array of engineered transgenic animals and high-throughput screening methods.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding potential collaborations and economic outcomes, emphasizing the inherent risks and uncertainties in biopharmaceutical discovery and development.

[object Object]
Preview
3.0
08-26Benzinga
Three Health Care Stocks You Won't Want to Overlook This Quarter

  • Oversold Stocks Opportunity: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies.

  • Zentek Ltd Performance: Zentek's stock has an RSI of 29.8, with a recent quarterly loss and a 33% decline over the past month, closing at $0.65.

  • Nano-X Imaging Ltd Update: Nano-X Imaging has an RSI of 27.5, reported a narrower-than-expected quarterly loss, and saw its stock drop 24% recently, closing at $3.89.

  • OmniAb Inc Developments: OmniAb's stock has an RSI of 26.7, announced a $30 million private placement, and experienced a 19% decline in the last five days, closing at $1.63.

[object Object]
Preview
8.5
08-25SeekingAlpha
OmniAb Plans to Secure $30 Million Through Private Stock Offering

  • Private Placement Agreement: OmniAb has finalized a private placement agreement to raise approximately $30 million by issuing 21,254,106 shares at $1.40 each.

  • Use of Proceeds: The net proceeds from this financing will be utilized for general corporate purposes, with the transaction expected to close around August 26, 2025.

  • Investor Participation: The financing round includes participation from both new and existing top-tier investors, as well as company officers and directors.

  • Stock Performance: Following the announcement, OABI stock experienced a decline of 10.81% in premarket trading on Monday.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OmniAb Inc (OABI) stock price today?

The current price of OABI is 1.97 USD — it has increased 4.79 % in the last trading day.

arrow icon

What is OmniAb Inc (OABI)'s business?

OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.

arrow icon

What is the price predicton of OABI Stock?

Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OmniAb Inc (OABI)'s revenue for the last quarter?

OmniAb Inc revenue for the last quarter amounts to 2.24M USD, decreased -46.33 % YoY.

arrow icon

What is OmniAb Inc (OABI)'s earnings per share (EPS) for the last quarter?

OmniAb Inc. EPS for the last quarter amounts to -0.14 USD, decreased -12.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for OmniAb Inc (OABI)'s fundamentals?

The market is revising Downward the revenue expectations for OmniAb, Inc. (OABI) for FY2025, with the revenue forecasts being adjusted by -11.11% over the past three months. During the same period, the stock price has changed by 15.20%.
arrow icon

How many employees does OmniAb Inc (OABI). have?

OmniAb Inc (OABI) has 114 emplpoyees as of December 05 2025.

arrow icon

What is OmniAb Inc (OABI) market cap?

Today OABI has the market capitalization of 283.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free